|
Related Articles |
Peering into review.
Nat Med. 2010 Mar;16(3):239
Authors:
PMID: 20208482 [PubMed - in process]
[...]
|
||||||||||||||||||||||
Peering into review. Nat Med. 2010 Mar;16(3):239 Authors: PMID: 20208482 [PubMed - in process] [...]
FDA initiative may crack wall of secrecy. Nat Med. 2010 Mar;16(3):244 Authors: Schubert C PMID: 20208488 [PubMed - in process] [...]
Vaccine funds will save lives. Nat Med. 2010 Mar;16(3):243 Authors: Willyard C PMID: 20208487 [PubMed - in process] [...]
Pharma spends big to buy influence. Nat Med. 2010 Mar;16(3):243 Authors: PMID: 20208486 [PubMed - in process] [...]
Obama’s budget boosts biomedicine. Nat Med. 2010 Mar;16(3):243 Authors: PMID: 20208485 [PubMed - in process] [...]
In Haiti, collapsed AIDS clinics fret over new challenges. Nat Med. 2010 Mar;16(3):242 Authors: Dolgin E PMID: 20208484 [PubMed - in process] [...]
Rare opportunities appear on the horizon to treat rare diseases. Nat Med. 2010 Mar;16(3):241 Authors: Torres C PMID: 20208483 [PubMed - in process] [...]
Patent disputes could trip up genome wide scans for disease. Nat Med. 2010 Mar;16(3):245 Authors: Borrell B PMID: 20208490 [PubMed - in process] [...]
Industry’s influence in biologics legislation examined. Nat Med. 2010 Mar;16(3):245 Authors: Dolgin E PMID: 20208489 [PubMed - in process] [...]
A timeline of the Wakefield retraction. Nat Med. 2010 Mar;16(3):248 Authors: PMID: 20208494 [PubMed - in process] [...] |
||||||||||||||||||||||
|
|
||||||||||||||||||||||